文献速递免疫规划传染病防控与疫情报告

成年沙鼠模型用于评估柯萨奇病毒A16疫苗候选物

An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates.
PubMed 文献 · Vaccine · 2019-07-24

研究建立60日龄成年沙鼠模型,腹腔接种高剂量(10^8.0 TCID50)CVA16临床分离株后出现后肢无力、瘫痪、震颤及神经症状死亡,病毒载量以脊髓和脑干最高。铝佐剂灭活疫苗初免加加强免疫可完全保护沙鼠免于CVA16攻击后的临床疾病和死亡,而80%对照动物出现明显症状并最终死亡。

要点

  • 成年沙鼠对高剂量CVA16感染敏感,可模拟神经和肌肉病理。
  • CVA16攻击后脊髓和脑干病毒载量高于其他组织。
  • 铝佐剂灭活疫苗初免加加强可完全保护沙鼠免于CVA16攻击。

核心结论

  • 成年沙鼠模型可用于研究CVA16致病机制和评估疫苗候选物。

研究设计与样本

  • 研究使用60日龄成年沙鼠,腹腔接种CVA16临床分离株,剂量为10^8.0 TCID50。
  • 疫苗评估采用铝佐剂灭活疫苗初免加加强免疫,随后进行CVA16攻击。

主要发现

  • 成年沙鼠接种CVA16后出现后肢无力、单侧或双侧后肢瘫痪、震颤及神经紊乱导致的死亡。
  • 实时RT-PCR显示脊髓和脑干病毒载量高于其他器官/组织。
  • 病理可见脊髓、脑干和心肌的神经元变性、神经元丢失和噬神经元现象,以及坏死性肌炎。
  • 铝佐剂灭活疫苗初免加加强免疫的沙鼠在CVA16攻击后无临床疾病和死亡。
  • 80%对照动物在CVA16攻击后出现明显临床症状,包括行动迟缓、单侧或双侧后肢瘫痪,并最终死亡。

关键数值与推荐

  • 成年沙鼠对CVA16感染的敏感剂量为10^8.0 TCID50。
  • 铝佐剂灭活疫苗初免加加强免疫对沙鼠CVA16攻击提供完全保护。
  • 对照动物在CVA16攻击后80%出现明显临床症状并最终死亡。

临床怎么用

  • 该模型可用于筛选和评估CVA16疫苗候选物及抗病毒药物。

局限性

  • 新生小鼠模型对CVA16感染的敏感期短是主要局限,本研究未报告成年沙鼠模型的其他局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A suitable animal model of CVA16 infection is crucial in order to understand its pathogenesis and to help develop antiviral vaccines or screen therapeutic drugs. The neonatal mouse model has a short sensitivity period to CA16 infection, which is a major limitation. In this study, we demonstrate that adult (60-day-old) gerbils are susceptible to CVA16 infection at high doses (108.0 TCID50). A clinical isolate strain of CVA16 was inoculated intraperitoneally into adult gerbils, which subsequently developed significant clinical symptoms, including hind limb weakness, paralysis of one or both hind limbs, tremors, and eventual death from neurological disorders. Real-time RT-PCR revealed that viral loads in the spinal cord and brainstem were higher than those in other organs/tissues. Histopathological changes, such as neuronal degeneration, neuronal loss, and neuronophagia, were observed in the spinal cord, brainstem, and heart muscle, along with necrotizing myositis. Gerbils receiving both prime and boost immunizations of alum adjuvant inactivated vaccine exhibited no clinical signs of disease or mortality following challenge by CVA16, whereas 80% of control animals showed obvious clinical signs, including slowness, paralysis of one or both hind limbs, and eventual death, suggesting that the CVA16 vaccine can fully protect gerbils against CVA16 challenge. These results demonstrate that an adult gerbil model provides us with a useful tool for studying the pathogenesis and evaluating antiviral reagents of CVA16 infection. The development of this animal model would also be conducive to screening promising CVA16 vaccine candidates as well as further vaccination evaluation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yao PP, Miao ZP, Xu F, et al. An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates. Vaccine. 2019. PMID: 31351798. doi:10.1016/j.vaccine.2019.07.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。